Cargando…

Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction

BACKGROUND: To explore long-term cardiovascular prognosis after myocardial infarction (MI) among patients with type 1 diabetes. METHODS: Patients with type 1 diabetes surviving 90 days after MI (n = 1508; 60% male, mean age = 62.1 years) or without any type of diabetes (n = 62,785) in Finland during...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerola, Anne M., Semb, Anne Grete, Juonala, Markus, Palomäki, Antti, Rautava, Päivi, Kytö, Ville
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450422/
https://www.ncbi.nlm.nih.gov/pubmed/36068573
http://dx.doi.org/10.1186/s12933-022-01608-3
_version_ 1784784518258884608
author Kerola, Anne M.
Semb, Anne Grete
Juonala, Markus
Palomäki, Antti
Rautava, Päivi
Kytö, Ville
author_facet Kerola, Anne M.
Semb, Anne Grete
Juonala, Markus
Palomäki, Antti
Rautava, Päivi
Kytö, Ville
author_sort Kerola, Anne M.
collection PubMed
description BACKGROUND: To explore long-term cardiovascular prognosis after myocardial infarction (MI) among patients with type 1 diabetes. METHODS: Patients with type 1 diabetes surviving 90 days after MI (n = 1508; 60% male, mean age = 62.1 years) or without any type of diabetes (n = 62,785) in Finland during 2005–2018 were retrospectively studied using multiple national registries. The primary outcome of interest was a combined major adverse cardiovascular event (MACE; cardiovascular death, recurrent MI, ischemic stroke, or heart failure hospitalization) studied with a competing risk Fine-Gray analyses. Median follow-up was 3.9 years (maximum 12 years). Differences between groups were balanced by multivariable adjustments and propensity score matching (n = 1401 patient pairs). RESULTS: Cumulative incidence of MACE after MI was higher in patients with type 1 diabetes (67.6%) compared to propensity score-matched patients without diabetes (46.0%) (sub-distribution hazard ratio [sHR]: 1.94; 95% confidence interval [CI]: 1.74–2.17; p < 0.0001). Probabilities of cardiovascular death (sHR 1.81; p < 0.0001), recurrent MI (sHR 1.91; p < 0.0001), ischemic stroke (sHR 1.50; p = 0.0003), and heart failure hospitalization (sHR 1.98; p < 0.0001) were higher in patients with type 1 diabetes. Incidence of MACE was higher in diabetes patients than in controls in subgroups of men and women, patients aged < 60 and ≥ 60 years, revascularized and non-revascularized patients, and patients with and without atrial fibrillation, heart failure, or malignancy. CONCLUSIONS: Patients with type 1 diabetes have notably poorer long-term cardiovascular prognosis after an MI compared to patients without diabetes. These results underline the importance of effective secondary prevention after MI in patients with type 1 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01608-3.
format Online
Article
Text
id pubmed-9450422
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94504222022-09-08 Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction Kerola, Anne M. Semb, Anne Grete Juonala, Markus Palomäki, Antti Rautava, Päivi Kytö, Ville Cardiovasc Diabetol Research BACKGROUND: To explore long-term cardiovascular prognosis after myocardial infarction (MI) among patients with type 1 diabetes. METHODS: Patients with type 1 diabetes surviving 90 days after MI (n = 1508; 60% male, mean age = 62.1 years) or without any type of diabetes (n = 62,785) in Finland during 2005–2018 were retrospectively studied using multiple national registries. The primary outcome of interest was a combined major adverse cardiovascular event (MACE; cardiovascular death, recurrent MI, ischemic stroke, or heart failure hospitalization) studied with a competing risk Fine-Gray analyses. Median follow-up was 3.9 years (maximum 12 years). Differences between groups were balanced by multivariable adjustments and propensity score matching (n = 1401 patient pairs). RESULTS: Cumulative incidence of MACE after MI was higher in patients with type 1 diabetes (67.6%) compared to propensity score-matched patients without diabetes (46.0%) (sub-distribution hazard ratio [sHR]: 1.94; 95% confidence interval [CI]: 1.74–2.17; p < 0.0001). Probabilities of cardiovascular death (sHR 1.81; p < 0.0001), recurrent MI (sHR 1.91; p < 0.0001), ischemic stroke (sHR 1.50; p = 0.0003), and heart failure hospitalization (sHR 1.98; p < 0.0001) were higher in patients with type 1 diabetes. Incidence of MACE was higher in diabetes patients than in controls in subgroups of men and women, patients aged < 60 and ≥ 60 years, revascularized and non-revascularized patients, and patients with and without atrial fibrillation, heart failure, or malignancy. CONCLUSIONS: Patients with type 1 diabetes have notably poorer long-term cardiovascular prognosis after an MI compared to patients without diabetes. These results underline the importance of effective secondary prevention after MI in patients with type 1 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01608-3. BioMed Central 2022-09-06 /pmc/articles/PMC9450422/ /pubmed/36068573 http://dx.doi.org/10.1186/s12933-022-01608-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kerola, Anne M.
Semb, Anne Grete
Juonala, Markus
Palomäki, Antti
Rautava, Päivi
Kytö, Ville
Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title_full Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title_fullStr Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title_full_unstemmed Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title_short Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
title_sort long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450422/
https://www.ncbi.nlm.nih.gov/pubmed/36068573
http://dx.doi.org/10.1186/s12933-022-01608-3
work_keys_str_mv AT kerolaannem longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction
AT sembannegrete longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction
AT juonalamarkus longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction
AT palomakiantti longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction
AT rautavapaivi longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction
AT kytoville longtermcardiovascularprognosisofpatientswithtype1diabetesaftermyocardialinfarction